The Pfizer logo is seen on the pharmaceutical company’s manufacturing plant, in Newbridge, Ireland.
| Photo Credit: Reuters

Pfizer Ltd has reported an 85% jump in net profit at ₹330.94 crore in the fourth quarter ended March 2025, boosted by a gain in exceptional item from completion of asset sale and transfer.

The company had posted a net profit of ₹178.86 crore in the corresponding quarter of preceding fiscal, Pfizer Ltd said in a regulatory filing.

Revenue from operations in the quarter under review stood at ₹591.91 crore as against ₹546.63 crore in the year-ago period, it added.

Total expenses in the fourth quarter were higher at ₹383.5 crore as compared to ₹377.9 crore in the corresponding period a year ago.

During the reporting quarter the company had an exceptional item gain of ₹172.81 crore from the completion of the transfer and sale of land at Thane along with structures and buildings to Zoetis Pharmaceutical Research Pvt Ltd, the filing said.

In the fiscal ended March 31, 2025 consolidated net profit was at ₹767.6 crore as compared to ₹551.33 crore in FY24. In FY25 revenue from operations stood at ₹2,281.35 crore as compared to ₹2,193.17 crore in FY24.

Pfizer Ltd said its board of directors have recommended a total dividend of ₹165 per equity share at ₹10 each for the financial year ended March 2025. This includes a final dividend of ₹35 per share, a special dividend of ₹100 per share in view of the company’s 75th year in India and a special dividend of ₹30 per share in view of the gain on transfer of assignment of leasehold land and building, the filing said.